

### **Listing of the Claims:**

The following listing of claims will replace all prior versions and listings of claims in the application.

1.-46. (Canceled)

45. (Currently Amended) A pharmaceutical composition comprising an isolated hyperimmune serum-reactive antigen ~~comprising an amino acid sequence of SEQ ID NO: 364 or an immunogenic fragment of SEQ ID NO: 364 comprising one or more of amino acid sequences 414-420, 427-437, 455-475, 494-510, fragment consisting of an amino acid sequence of 399-417, 503-519, 544-563, 489-556, 386-458, or 458-624 of SEQ ID NO:364.~~

46. (Currently Amended) The pharmaceutical composition of claim 45, wherein the hyperimmune serum-reactive antigen ~~or~~ fragment is directed against *S. agalactiae*.

47. (Currently Amended) The pharmaceutical composition of claim 45, further defined as comprising at least two different hyperimmune serum-reactive antigens ~~and/or~~ fragments.

48. (Previously Presented) The pharmaceutical composition of claim 47, wherein the at least two different hyperimmune serum-reactive antigens ~~and/or~~ fragments are both directed against *S. agalactiae*.

49. (Previously Presented) The pharmaceutical composition of claim 45, further comprising an immunostimulatory substance.

50. (Previously Presented) The pharmaceutical composition of claim 49, wherein the immunostimulatory substance is a polycationic polymer, an immunostimulatory deoxynucleotide (ODN), a peptide containing at least two LysLeuLys motifs, a neuroactive compound, alum, or a Freund's complete or incomplete adjuvant.

51. (Withdrawn) The pharmaceutical composition of claim 50, wherein the polycationic polymer is a polycationic peptide.

52. (Withdrawn) The pharmaceutical composition of claim 50, wherein the neuroactive compound is human growth hormone.

53. (Previously Presented) The pharmaceutical composition of claim 45, further defined as a vaccine.

54. (Previously Presented) The pharmaceutical composition of claim 53, further defined as a vaccine for treatment and/or prevention of *S. agalactiae* infection.

55-60. (Canceled)

61. (Currently Amended) A pharmaceutical composition comprising:

- (a) ~~an isolated hyperimmune serum-reactive antigen comprising an amino acid sequence of SEQ ID NO: 364 or an immunogenic fragment of SEQ ID NO: 364 comprising one or more of amino acid sequences 414-420, 427-437, 455-475, 494-510, fragment consisting of an amino acid sequence of 399-417, 503-519, 544-563, 489-556, 386-458, or 458-624 of SEQ ID NO: 364; and~~
- (b) an immunostimulatory substance.